Navigation Links
Halozyme Therapeutics Reports First Quarter 2011 Financial Results
Date:5/6/2011

replay ID # 371588. The conference call will be broadcast live over the Internet at www.halozyme.com and the replay will be available on the company's Web site for seven days.

About Halozyme TherapeuticsHalozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche and with Baxter to apply Enhanze technology to biological therapeutics including Herceptin®, MabThera® and immunoglobulin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.

Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the timing and scope of our clinical trials as well as expected activities under our collaborative partnerships) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statemen
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
2. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
3. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
4. Halozyme Receives $5.5 Million Payment From Baxter
5. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
6. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
8. Halozyme Therapeutics to Present at Upcoming Investor Conferences
9. Halozyme Therapeutics to Host Research Day for Investors and Analysts
10. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
11. Halozyme Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... SAN FRANCISCO , July 29, 2015 /PRNewswire/ ... trialling mobile molecular testing for applications in food ... Ubiquitome,s hand-held, battery powered real-time PCR device, the ... the farm right through to the supermarket shelf ... world. This includes involvement in animal disease control ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... announced its GHS Label Guide . To align chemical container labeling with ... guide includes explanations of label components, an example of an accurate label, and ...
(Date:7/29/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX) announced today ... released on Thursday, August 13, 2015, before the open ... will host a conference call to discuss the financial ... outlining the financial results and business update will be ... call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference Pfenex ...
(Date:7/29/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... to announce that the final design specifications of ... Prototypes for industrial and regulatory testing will now ... CE mark clearance to market the injector in ... (Photo: http://photos.prnewswire.com/prnh/20150729/248373 )  The ...
Breaking Biology Technology:AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Brady Announces a New GHS Label Guide 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5
... CAMBRIDGE, Mass., Oct. 1 Idenix Pharmaceuticals, Inc. (Nasdaq: ... discovery and development of drugs for the treatment of ... IDX184, the company,s lead hepatitis C development program, have ... of the American Association for the Study of Liver ...
... , Enerkem,s future biofuels plant ... , MONTREAL, Oct. 1 /PRNewswire/ - Enerkem, a leading waste-to-biofuels ... of a community energy initiative that will heat a Strathcona ... its process employed at its Edmonton waste-to-biofuels plant. , The ...
... QUEBEC CITY, Oct. 1 /PRNewswire-FirstCall/ - Medicago Inc. ... highly effective and affordable vaccines based on proprietary ... that it has initiated a Phase I human ... ("H5N1 vaccine"). Enrolment is ongoing and vaccination has ...
Cached Biology Technology:Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 3Enerkem Announces Unique Community Energy Project 2Medicago begins human clinical testing with its avian flu pandemic vaccine 2
(Date:7/7/2015)... Calif. , July 7, 2015  Based ... market, Frost & Sullivan recognizes Credence ID, LLC ... Entrepreneurial Company of the Year Award. Credence ... to aid in its mission of offering enrollment ... populations globally. As Credence ID was formed by ...
(Date:7/2/2015)... , June 25, 2015 ... addition of the "Next Generation Biometrics Market by ... 2020" report to their offering. The ... Billion by 2020, at a CAGR of 17.9% between ... the leading application for the market. Safran SA ...
(Date:6/30/2015)... , June 30, 2015 Genisphere ... as CEO to help further develop Genisphere,s therapeutics capabilities ... partnering experience, having spent much of the last 25 ... Amgen, Baxter Bioscience, and Johnson & Johnson. Tom started ... Technology and Biotech Corporate Finance. He graduated from Dartmouth ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... 19, 2011) When researchers discovered the primary genetic defect ... up a new realm of research into treatment and a ... to clone the defective gene and study its effects in ... Chapel Hill have developed a technique for observing the defects ...
... presumably not lead to a permanent El Nio state ... drawn by an international team of researchers after it ... The growth rings of these fossils indicate that there ... during the last prolonged interglacial phase of the Earth,s ...
... a bidirectional relation between schizophrenia and epilepsy. The study ... the International League Against Epilepsy (ILAE), reports that patients ... develop schizophrenia and those with schizophrenia were close to ... Prior clinical studies have shown a prevalence of psychosis ...
Cached Biology News:The cellular intricacies of cystic fibrosis 250-million-year-old clam shells provide indications of future of El Nino phenomenon 2Study finds bidirectional relationship between schizophrenia and epilepsy 2
... Ciphergen's ProteinChip arrays have been ... from biological samples. A variety of ... of proteins according to their unique ... different spots, allowing side-by-side sample comparison, ...
... have been developed for affinity capture ... variety of ProteinChip chemical surfaces allow ... their unique biochemical properties. Each chip ... sample comparison, and the chips are ...
... Use this kit to purify genomic DNA from plants ... bead beating in a deep well plate using large ... requires a high velocity plate shaker (available through Mo ... a silica membrane spin filter plate. The DNA is ...
... The DNA Engine instrument is ... Unprecedented thermal uniformity and ... and block-to-block. This rugged ... cycler, it's a platform for new ...
Biology Products: